Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
Holding BLFS?
Track your performance easily
BLFS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.50 - $28.88
Previous CloseN/A
Volume44.73K
Average Volume (3M)296.47K
Market Cap
$1.23B
Enterprise Value$1.16B
Total Cash (Recent Filing)$1.41M
Total Debt (Recent Filing)$2.84M
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Mar 13, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding46,387,215
10 Day Avg. Volume189,808
30 Day Avg. Volume296,472
Standard Deviation0.20
R-Squared0.27
Alpha0.00501
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.01
Price to Cash Flow (P/CF)64.30
P/FCF Ratio64.30
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue9.41
Enterprise Value/Gross Profit24.84
Enterprise Value/Ebitda-74.28
Forecast
1Y Price Target
$30.78Price Target Upside15.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
BioLife Solutions News
PremiumCompany Announcements
BioLife Solutions Strengthens Board with Tony J. Hunt Appointment
Bulls Say, Bears Say
Bulls Say
Core Business FocusThe divestment allows BioLife to focus on higher margin, proprietary, and recurring core businesses highlighted by their biopreservation media.
Financial StrengthBioLife Solutions strengthened its cash position significantly, with an estimated pro forma cash position of approximately $115M.
Strategic RealignmentBLFS shares have rebounded as the company has executed on its strategic realignment, refocusing on its 'sticky' Cell and Gene Therapy tools that become integrated into customer therapy, driving reliable and repeat business.
Bears Say
Business PerformanceBiolife's freezer business lines represented a high-spend and low-margin segment, which weighed on top-line growth and the share price.
Projected RevenuesProjected revenues for the next 12 months are lowered, resulting in a reduced price target of $27 per share.
Revenue GuidanceBioLife lowered revenue guidance to $98M-$100M, from $99M-$101M, to factor in the reduction of the SciSafe divestiture.
---
Ownership Overview
21.99% Insiders
24.39% Mutual Funds
0.46% Other Institutional Investors
35.53% Public Companies and
Individual Investors
BLFS FAQ
What was BioLife Solutions’s price range in the past 12 months?
BioLife Solutions lowest stock price was $14.50 and its highest was $28.88 in the past 12 months.
What is BioLife Solutions’s market cap?
BioLife Solutions’s market cap is $1.23B.
When is BioLife Solutions’s upcoming earnings report date?
BioLife Solutions’s upcoming earnings report date is Mar 13, 2025 which is in 60 days.
How were BioLife Solutions’s earnings last quarter?
BioLife Solutions released its earnings results on Nov 12, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.038.
Is BioLife Solutions overvalued?
According to Wall Street analysts BioLife Solutions’s price is currently Undervalued.
Does BioLife Solutions pay dividends?
BioLife Solutions does not currently pay dividends.
What is BioLife Solutions’s EPS estimate?
BioLife Solutions’s EPS estimate is -0.06.
How many shares outstanding does BioLife Solutions have?
BioLife Solutions has 46,387,215 shares outstanding.
What happened to BioLife Solutions’s price movement after its last earnings report?
BioLife Solutions reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went down -9.019%.
Which hedge fund is a major shareholder of BioLife Solutions?
Among the largest hedge funds holding BioLife Solutions’s share is Royce & Associates LLC. It holds BioLife Solutions’s shares valued at 21M.
---
BioLife Solutions Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.78 (15.67% Upside)
$30.78 (15.67% Upside)
Hedge Fund Trend
Decreased
By 75.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.89%
12-Months-Change
Fundamentals
Return on Equity
-9.87%
Trailing 12-Months
Asset Growth
-7.17%
Trailing 12-Months
Company Description
BioLife Solutions
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
---
BLFS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and margin expansion driven by the cell processing platform. The strategic divestiture of the SciSafe BioStorage business is expected to streamline operations and improve the company's financial position. However, the reduction in overall revenue guidance and the dependency on a small customer base are notable concerns.Read More>---
BLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services
---
BLFS Stock 12 Month Forecast
Average Price Target
$30.78
▲(15.67% Upside)
Technical Analysis
Fate Therapeutics
―
AxoGen
―
Staar Surgical
―
Alphatec Holdings
―
TransMedics Group
―
Accelerate Diagnostics
―
Best Analysts Covering BLFS
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+46.84%
reiterated a buy rating 2 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +46.84% per trade.
---